Results 341 to 350 of about 152,178 (350)

Emtansine/pertuzumab/trastuzumab/trastuzumab

Reactions Weekly
openaire   +1 more source

Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study Group

Journal of Clinical Oncology, 2005
Francesco Cognetti, Ana Lluch, Kenneth J O'byrne   +2 more
exaly  

Trastuzumab

Reactions Weekly, 2015
openaire   +2 more sources

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Lancet Oncology, The, 2013
Sandra M Swain, Vladimir Semiglazov, Mario Campone   +2 more
exaly  

Towards personalized treatment for early stage HER2-positive breast cancer

Nature Reviews Clinical Oncology, 2019
Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Carmine De Angelis   +2 more
exaly  

Paclitaxel/trastuzumab/trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source

Osimertinib/Trastuzumab-deruxtecan/Trastuzumab-emtansine

Reactions Weekly
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2007
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2003
openaire   +1 more source

Trastuzumab

Reactions Weekly, 2014
openaire   +1 more source